What is Biogen's share of net profit from sage therapeutics, percent?

Biogen (BIIB) reported share of net profit from sage therapeutics, percent of 50.0% in Q1 2026.

How has Biogen's share of net profit from sage therapeutics, percent changed year-over-year?

Biogen's share of net profit from sage therapeutics, percent decreased by 0.0% year-over-year, from 50.0% to 50.0%.

Share of net profit from sage therapeutics, Percent

Biogen Share of net profit from sage therapeutics, Percent remained flat by 0.0% to 50.0% in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from 50.0% to 50.0%.

Analysis

StatementBalance Sheet Statement

SectionOther

First reportedQ3 2023

Last reportedQ1 2026

Metric ID: other_share_of_net_profit_from_sage_therapeutics_percent

Historical Data

9 periods

	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q1 '25	Q2 '25	Q3 '25	Q1 '26
Value	50%	50%	50%	50%	50%	50%	50%	50%	50%
QoQ Change	—	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%
YoY Change	—	—	—	—	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%

Range50% – 50%

CAGR+0.0%

Avg YoY Growth+0.0%

Median YoY Growth+0.0%

Current Streak8+ quarters growth

Frequently Asked Questions

What is Biogen's share of net profit from sage therapeutics, percent?: Biogen (BIIB) reported share of net profit from sage therapeutics, percent of 50.0% in Q1 2026.
How has Biogen's share of net profit from sage therapeutics, percent changed year-over-year?: Biogen's share of net profit from sage therapeutics, percent decreased by 0.0% year-over-year, from 50.0% to 50.0%.